Ga-68 dotatate: evidence, FDA status and research

A scan that finds a certain type of tumor. Studies show it spots tumors better than the older scan.

Sold for

Ga-68 dotatate PET is the scan that finds neuroendocrine tumors the older octreotide scan missed and decides who is eligible for radioligand therapy.

Studies say

Head-to-head imaging studies show higher accuracy than the older scan and frequent changes in management, which supports its approved diagnostic use at a B.

Why grade B. As a diagnostic, Ga-68 dotatate was approved on accuracy studies, not randomized trials. The study cited here, 78 patients with known or suspected neuroendocrine tumors imaged with both Ga-68 dotatate PET and the older In-111 pentetreotide scan, found the PET scan more accurate and changed management in 36% of patients. ¹ Multiple consistent studies exist and the scan is now standard practice, but the evidence type keeps it at B under our definitions. ¹²

FDA. Approved. Gallium Ga-68 dotatate was approved by the FDA on June 1, 2016 as NETSPOT (Advanced Accelerator Applications, now Novartis), a kit for preparing a PET imaging agent to localize somatostatin receptor-positive neuroendocrine tumors in adults and children. It is a single intravenous injection given before a PET scan, not a treatment. ²

Written from 2 cited sources. Fact-checked 2026-10-27: 12 claims checked, 1 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Finding neuroendocrine tumors on a scan
Can a US doctor prescribe it?: Yes, FDA approved for scanning for neuroendocrine tumors.
Properly tested in people?: Partly: accuracy studies, such as one of 78 patients, rather than large trials.

Evidence checklist

Randomised controlled trial Accuracy study, not randomizedno
Human study over 100 people 78 patients in the cited studyno
More than one research group Single study in the articleno information
Clinical outcomes, not surrogate markers Changed management in 36%yes
Human safety data beyond case reports No treatment-requiring adverse eventsyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Ga-68 dotatate is a radioactive imaging agent with three parts. The first is dotatate (also called DOTA-Tyr3-octreotate). It is a lab-made version of the hormone somatostatin, with eight amino acids. The second is the chelator DOTA, which holds the metal. The third is gallium-68. This isotope emits positrons and has a 68-minute half-life. The kit, NETSPOT, is mixed in the nuclear pharmacy with gallium-68 from a generator. It is injected shortly before a PET/CT scan. ²

Neuroendocrine tumors arise from hormone-producing cells in the gut, pancreas and lungs. Most carry large numbers of somatostatin receptors on their surface. For decades, doctors imaged them with In-111 pentetreotide (Octreoscan). It is a gamma-camera agent with poorer resolution. Ga-68 dotatate PET replaced it after approval in 2016. ¹²

How it works

Dotatate binds somatostatin receptor subtype 2 with high affinity. After injection, the peptide circulates. It attaches to tissue rich in receptors, and cells take it in. Within about an hour, the gallium-68 builds up in tumor deposits. The PET camera detects the positrons and maps them onto a CT image. Normal tissues with somatostatin receptors also light up. These include the pituitary, spleen and adrenal glands. The reader allows for this. The same peptide labeled with lutetium-177 instead of gallium-68 becomes a therapy, Lutathera. So a positive dotatate scan is the gateway to that treatment. ¹²

What human research shows

A Vanderbilt study supported approval. It enrolled 97 consecutive patients with known or suspected neuroendocrine tumors. Of these, 78 had both Ga-68 dotatate PET/CT and In-111 pentetreotide imaging. Ga-68 dotatate was equal or better than the older scan in all 78 patients. It correctly picked out 3 patients for peptide receptor radiotherapy. The older scan had misclassified them. It changed the treatment plan for 36% of participants. Radiation exposure was lower, and the scan took one visit instead of two days. ¹

Based on this and similar studies, the label says the scan was tested in patients with known or suspected disease. It warns that uptake is not specific to neuroendocrine tumors. Other tumors can have somatostatin receptors. So can inflammatory conditions. Both can produce false positives. ²

Study	Model	Finding
Deppen 2016 head-to-head study	Humans, n=78 completing both scans (97 enrolled), Ga-68 dotatate PET/CT vs In-111 pentetreotide	Ga-68 dotatate PET was more accurate and changed management in 36% of patients with no adverse events requiring treatment. ¹
NETSPOT prescribing information	FDA label, 2016	Approved for PET localization of somatostatin receptor-positive neuroendocrine tumors in adults and children; uptake is not specific to these tumors. ²

Safety

Adverse reactions are rare. None needing treatment occurred in the 78-patient study. The radiation dose is modest and lower than the older scan's. The main risk in reading the scan is a false positive from benign uptake. Patients on long-acting octreotide or lanreotide are usually scanned just before their next dose. Those drugs occupy the same receptor and can reduce tumor uptake. ¹²

Questions for your clinician

What will this scan change about my treatment plan?
Do I need to time the scan around my octreotide or lanreotide dose?
What does a false-positive uptake look like?

Questions people ask

Is Ga-68 dotatate FDA-approved?

Yes. NETSPOT was approved in June 2016 for PET imaging of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. ²

Is Ga-68 dotatate a treatment?

No. It is a diagnostic imaging agent. The therapeutic version uses the same peptide attached to lutetium-177 (Lutathera). A positive Ga-68 dotatate scan is how patients are selected for it. ²

How is it better than the Octreoscan?

PET has much higher resolution than the gamma camera used for In-111 pentetreotide. The whole study takes one visit instead of two days. Radiation exposure is lower. In direct comparison, it found more lesions and changed management in about a third of patients. ¹

Can the scan be wrong?

Yes. Somatostatin receptors are present on normal pituitary, spleen and adrenal tissue, on some other tumors, and at sites of inflammation. So uptake has to be read alongside the CT and the clinical picture. ²

Citations

Deppen 2016, Journal of Nuclear Medicine: 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors doi.org
Novartis: NETSPOT (kit for preparation of gallium Ga-68 dotatate injection) prescribing information novartis.com